Completed PHASE1 INTERVENTIONAL NCT00003792

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Dendritic Cell Immunotherapy of Metastatic Melanoma - A Phase I Trial

Sponsor: Baylor Health Care System

Interventions MART-1 antigen filgrastim flu matrix peptide p58-66 gp100 antigen in vitro-treated peripheral blood stem cell transplantation recombinant MAGE-3.1 antigen tyrosinase peptide

Updated 5 times since 2017 Last updated: Jun 25, 2013 Started: Apr 30, 1999 Completion: Oct 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Melanoma (Skin) and is currently completed. Baylor Health Care System leads this study, which shows 5 recorded versions since 1999 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Apr 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Baylor Health Care System
National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dallas, United States